Scientific Publications
Abstracts, Posters, and Presentations
Hamilton T, Patel N, Sumner M, Solomon D, Kerney D. Initial Results from a Patient Experience Program in Patients Receiving MMX® Mesalazine for the Treatment of Ulcerative Colitis. Presented at the Canadian Digestive Diseases Week Annual Conference, Toronto, Ontario, Canada, February 2010.
Hamilton T, Patel N, Sumner M, Solomon D, Kerney D. Preliminary Outcomes from an MMX® Mesalazine Patient Experience Programme in Patients with Ulcerative Colitis. Presented at the 5th Congress of the European Crohn's and Colitis Organisation, Prague, Czech Republic, February 2010.
Antonucci D, Manos M, Kerney DL, Lopez FA. Lisdexamfetamine Dimesylate as Treatment for Attention-Deficit/Hyperactivity Disorder in Children Previously Treated With Osmotic-Release Oral System-Methylphenidate: Parental Impressions. Presented at the European Psychiatric Association 18th European Congress of Psychiatry, Munich, Germany, February 2010.
Newman D, Green L. Patients' Experience with Darifenacin: Results of a Community-based Survey in Overactive Bladder Patients. Presented at the Society for Urodynamics and Female Urology Annual Meeting, St Petersburg, Florida February 2010.
Hamilton T, Patel N, Sumner M, Solomon D, Kerney D. Preliminary Outcomes from the MMX® Mesalamine Patient Experience Program in Patients with Ulcerative Colitis. Presented at the 8th Annual Advances in Inflammatory Bowel Diseases Research Conference, Hollywood, FL, December 2009.
Babcock T, Shepski J, Manos M, Antonucci D, Kerney D. Patient Experience and Satisfaction with Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder Who Were Previously Treated With Mixed Amphetamine Salts Extended Release. Presented at U.S. Psychiatric & Mental Health Congress, Las Vegas, NV, November 2009.
Hamilton T, Sumner M, Solomon D, Kerney D. MMX® Mesalamine Treatment for Ulcerative Colitis: Preliminary Outcomes from a Patient Experience Program. Presented at the Annual Meeting of the American College of Gastroenterology, San Diego, CA, October 2009.
Manos M, Kerney DL, Lopez FA, Antonucci D. Lisdexamfetamine Dimesylate Treatment for Adults With Attention-Deficit/Hyperactivity Disorder Previously Treated With Osmotic-Release Oral System-Methylphenidate: Patient Impressions. Presented at the 61st Institute for Psychiatric Services, New York, NY, October 2009.
Antonucci D, Kerney DL, Lopez FA, Manos M. Lisdexamfetamine Dimesylate as Treatment for Attention-Deficit/Hyperactivity Disorder in Adults Previously Treated With Immediate-Release Stimulants: Patient Impressions. Presented at the 61st Institute for Psychiatric Services, New York, NY, October 2009.
Hunt P, Slater J, Antonucci D, Kerney DL, Lopez FA, Manos M. Lisdexamfetamine Dimesylate as Treatment for Attention-Deficit/Hyperactivity Disorder in Children Previously Treated With Osmotic-Release Oral System-Methylphenidate: Parental Impressions. Presented at the 21st Annual International Conference on AD/HD, Cleveland, OH, October 2009.
Antonucci D, Kerney D, Lopez FA, Manos M. Patient Experience and Satisfaction With Lisdexamfetamine Dimesylate in Adults With ADHD. Presented at the 2009 Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
Manos M, Antonucci D, Kerney D, DeLeon A. Patient Experience and Satisfaction With Lisdexamfetamine Dimesylate in Adults With ADHD Who Were Previously Treated With Mixed Amphetamine Salts Extended Release. Presented at the 2009 Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, FL, April 2009.
Kerney DL, Ford R, Gotz V. Patient Assessment of Desonide Hydrogel for the Treatment of Mild to Moderate Atopic Dermatitis. Presented at the 2009 Annual Meeting of the American Academy of Dermatology, San Francisco, CA, March 2009.
Manos M, Antonucci D, Kerney DL. Lisdexamfetamine Dimesylate as Treatment for Attention-Deficit/Hyperactivity Disorder in Children Previously Treated With Mixed Amphetamine Salts Extended Release: Parental Impressions. Presented at CHADD's 20th Annual International Conference on Attention Deficit/Hyperactivity Disorder, Anaheim, CA, November 2008.
Antonucci D, Kerney DL, Lopez FA, Kunins C, Manos M. Parental Impressions and Experiences With Lisdexamfetamine Dimesylate Treatment in Children Diagnosed With Attention-Deficit/Hyperactivity Disorder. Presented at U.S. Psychiatric & Mental Health Congress, San Diego, CA, November 2008.
Manos M, Antonucci D, Kerney DL. Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder: Parental Impressions and Experiences. Presented at the American Psychiatric Association 161st Annual Meeting, Washington DC, May 2008.
Onel E, Kerney DL, Kolsun K, Rogers MR. Patients' Perceptions of the Effect of Euflexxa™ (hyaluronic acid) on Knee Pain Induced Difficulties with Activities of Daily Living and Social or Leisure Activities. Presented at the Osteoarthritis Research Society International World Congress on Osteoarthritis, Fort Lauderdale, FL, December 2007.
Kane J, Kujawa M, Kerney D, et al. National Adherence Initiative in Schizophrenia: Assessing the Risk of Partial- and Non-Adherence in Patients with Schizophrenia. Presented at the US Psychiatric and Mental Health Congress, Orlando, FL, October 2007.
Kane J, Najarian D, Kujawa M, Kerney D, et al. National Adherence Initiative in Schizophrenia: Assessing the Risk of Partial- and Non-Adherence in Patients with Schizophrenia. Presented at the 59th Institute on Psychiatric Services, New Orleans, LA, October 2007.
Kerney DL, Paradis D, Lucrezia L, Brunton S. Self-Reported Impressions of Insulin Detemir Among Patients with Type 2 Diabetes: Insulin-Naïve vs. Prior Insulin Users. Diabetes.
2007;June Supplement (abstract 2120-PO).
Kerney DL, LeVine P. Feasibility of a Feedback Initiative for Facilitating Patient Engagement and Physician-Patient Communications. Presented at AcademyHealth Annual Research Meeting, Orlando, FL, June 2007.
Kane J, Kujawa M, Kerney D, et al. National Adherence Initiative in Schizophrenia: Assessing the Risk of Partial- and Non-Adherence in Patients with Schizophrenia. Presented at the American Psychiatric Association Annual Meeting, San Diego, CA, May 2007.
Kerney DL, LeVine P. New Audience for Patient-Reported Outcomes (PRO) Data: Patients. Presented at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual International Meeting, Arlington, VA, May 2007.
Kerney DL, Paradis D, Brunton S. Patient Perceptions of Insulin Detemir as Reported Through a Patient-Physician Communication Survey Study. Presented at The Insulin Congress, Washington, DC, November 2006. Insulin 2007;2(2):S26.
LeVine P, Ostmeyer D. Structured Insight into Patients: Learning What Patients Really Think about Your Product. Presented at Patient-Centric Marketing: Gaining Consumer Trust and Developing Loyalty, Princeton, NJ. September 2006.
Kerney DL, LeVine P. Combining Education and Patient-Reported Outcomes in Patient-Physician Communication Interventions. Presented at the Drug Information Association 42nd Annual Meeting, Philadelphia, PA, June 2006.
Kerney DL, LeVine P. Physician Impressions and Uses of Patient-Reported Outcomes Data. Presented at the International Society for Pharmacoeconomics and Outcomes Research 11th Annual International Meeting, Philadelphia, PA, May 2006.
Trattler W, Katsev D, Kerney D. Association of Self-Reported Compliance with Topical Cyclosporine A Emulsion 0.05% (tCSA) and Onset of Effects of Increased Tear Production. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 2006.
Stoloff S, Samuels S, Braman S, Brown C, Kerney D, Cicale M. High Satisfaction with Fluticasone Propionate/Salmeterol via Diskus Reported During Experience Program in Patients with COPD. Presented at the American College of Chest Physicians - CHEST 2005, Montreal, Quebec, Canada, October 2005.
Kerney DL, Paradis D. Evaluation of the Self-Reported Experiences of Patients Treated with Lamotrigine for Bipolar Disorder. Presented at the 18th Annual US Psychiatric & Mental Health Congress, Las Vegas, NV, November 2005.
Kerney D, Paradis D, Lucrezia L. A Naturalistic Study of Patients Treated for Rosacea with Sodium Sulfacetamide and Sulfur. Presented at the American Academy of Dermatology, Academy '05, Chicago, IL, July 2005.
Wulf SS, LeVine PM. An Assessment of Disability and Medication Satisfaction Among Patients Treated with Controlled-Release Paroxetine Hydrochloride. Presented at the 17th Annual U.S. Psychiatric & Mental Health Congress, San Diego, CA, November 2004.
LeVine PM, Paradis D. A Real World Assessment of Patients with Acne Vulgaris Treated with Tretinoin Gel. Presented at the American Academy of Dermatology, Academy '04, New York, NY, July 2004.
Paradis D, LeVine PM. Real World Use and Impact of Desloratadine for Treatment of Allergy Symptoms. Presented at the American Academy of Allergy, Asthma & Immunology, 60th Annual Meeting, San Francisco, CA, March 2004.
Netherton DR, Schmeichel CJ, Kerney DL. Self-Reported Patient Experience Data, Provided to Physicians At The Point Of Care, Offer An Important Complement to Traditional Efficacy Data and Enable the Derivation of Practice-Wide Treatment Guidelines. Presented at the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 6th Annual European Congress, Barcelona, Spain, November 2003.
Paradis D. A Real World Assessment of Seasonal and Year-Round Allergy Sufferers Treated with Desloratadine. Presented at the American College of Allergy, Asthma & Immunology, Annual Meeting, New Orleans, LA, November 2003.
Fuhrmann CP, Paradis D. Use of Real-World Experience Data in Patients Treated with Formoterol Fumarate Inhalation Powder. Presented at the American College of Chest Physicians, CHEST 2003 National Conference, Orlando, FL, October 2003.
Kerney DL. Assessing Self-Reported Use of Allergy Medications and Their Impact on Symptoms. Presented at Drug Information Association 4th Annual Workshop on Pharmaceutical Outcomes Research, Newport, RI, October 2002.
Kerney D. Real-World Treatment with Desloratadine in Seasonal Allergic Rhinitis (SAR) Patients. Presented at the American College of Allergy, Asthma & Immunology, Annual Meeting, San Antonio, TX, Spring 2002.
Graham JP, Kerney D, LeVine P. Assessment of Standard Medical Care in Patients with Type 2 Diabetes Mellitus. Diabetes 2002;51(suppl. 2):A-274. Presented at the American Diabetes Association, 62nd Scientific Sessions, San Francisco, CA, June 2002.
Kerney D, LeVine P, Wright R, Graham J. Is Control of Hemoglobin A1C Levels Associated with Control of Other Cardiovascular Parameters Important For Patients with Type 2 Diabetes Mellitus? Diabetes 2002;51(suppl. 2):A-274. Presented at the American Diabetes Association, 62nd Scientific Sessions, San Francisco, CA, June 2002.
Graham JP, Kovalick L, Kerney D. Control of Important Clinical Parameters for Patients with Type 2 Diabetes Mellitus. Diabetes 2002;51(suppl. 2):A-274. Presented at the American Diabetes Association, 62nd Scientific Sessions, San Francisco, CA, June 2002.
Peterson C, Lane J, Hu H, et al; on behalf of the US Migraine Study Protocol Investigators. Migraine Treatment with Rizatriptan-Effects on Work Loss in Naturalistic Setting. Presented at the American Academy of Neurology, 53rd Annual Meeting, Philadelphia, PA, May 2001.
Hu H, Raskin N, Cowan R, et al.; on behalf of the US Migraine Study Protocol Investigators. Migraine Attack Treatment with Rizatriptan-Timing of Medication Use and Clinical Outcomes. Presented at the American Academy of Neurology, 52nd Annual Meeting, San Diego, CA, May 2000.
Cutrer FM, Jamieson D, Hu H, et al.; on behalf of the US Migraine Study Protocol Investigators. Effectiveness of Different Oral Formulations of Rizatriptan in Treating Migraine in Naturalistic Setting. Presented at the American Headache Society, 42nd Annual Meeting, Montreal, Quebec, June 2000.
Landy S, Mauskop A, Hu H, et al.; on behalf of the US Migraine Study Protocol Investigators. Real World Experiences in Migraine Treatment with Rizatriptan in Patients Previously Treated by Other Oral Triptans. Presented at the American Headache Society, 42nd Annual Meeting, Montreal, Quebec, June 2000.
Solomon S, Frishberg, B Hu XH, et al.; on behalf of the US Migraine Study Protocol Investigators. Improved Migraine Treatment Outcomes with Rizatriptan in Triptan-Naïve Patients: A Naturalistic Study. Presented at the American Headache Society, 42nd Annual Meeting, Montreal, Quebec, June 2000.
Manuscripts
Antonucci D, Manos M, Kunins C, Lopez FA, Kerney DL. Patient Experience and Satisfaction With Lisdexamfetamine Dimesylate in Adults With ADHD. Primary Psychiatry. 2010;17(6):48-57.
Antonucci D, Kunins C, Manos M, Lopez FA, Kerney DL. Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric Attention-Deficit/Hyperactivity Disorder Using a Parental Survey. CNS Spectrums. 2010;15(4)248-256.
AAntonucci D. Assessing Effects of Treatment for Pediatric ADHD Using a Parental Survey. Psychiatry Weekly. 2010;5(8).
Kerney DL, Brunton S. Self-reported impressions of insulin detemir among patients with type 2 diabetes: insulin-naïve vs. prior insulin users. Medicine On-Line and Pharmacy On-Line. February 2008. Available at: http://www.priory.com/medicine/insulin_determir.htm.
Kerney DL, Paradis D, Brunton S. Patient perceptions of insulin detemir as reported through patient telephone surveys. Current Medical Research and Opinion. 2007;23(9):2043-2049.
Trattler W, Katsev D, Kerney D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of effects of increased tear production as assessed through patient surveys. Clinical Therapeutics. 2006;28(11):1848-1856.
Stoloff S, Samuels S, Kerney D, Brown CP. Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial. Medscape General Medicine. 2006;8(1):86.
Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Current Medical Research and Opinion. 2005;21(7):1057-1063.
Jamieson D, Cutrer FM, Goldstein J, et al.; on behalf of the United States Migraine Study Protocol (USMAP) Investigators. Real-world experiences in migraine therapy with rizatriptan. Headache: The Journal of Head and Face Pain. 2003;43(3):223-230.
Hu XH, Raskin NH, Cowan R, et al.; on behalf of the United States Migraine Study Protocol (USMAP) Investigators. Treatment of migraine with rizatriptan: when to take the medication. Headache: The Journal of Head and Face Pain. 2002;42(1):16-20.
Solomon S, Frishberg, B Hu XH, et al. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study. Clinical Therapeutics. 2001;23(6):886-900.
Scientific Publications: 2009-2010
Scientific Publications: 2006-2008
Scientific Publications: 2003-2005
Scientific Publications: 2000-2002
Scientific Publications PDF
|
